Experienced in Small for Gestational Age

Kristina Casteels

UZ Gasthuisberg, UZ Leuven
Leuven, VLG, BE 
Experienced in Small for Gestational Age
UZ Gasthuisberg, UZ Leuven
Leuven, VLG, BE 
OverviewLocationsClinical Research

Overview

Kristina Casteels practices in Leuven, Belgium. Ms. Casteels is rated as an Experienced expert by MediFind in the treatment of Small for Gestational Age. Her top areas of expertise are Type 1 Diabetes (T1D), Low Blood Sugar, Hirsutism in Women, and Macrosomia.

Her clinical research consists of co-authoring 68 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

UZ Gasthuisberg, UZ Leuven
Leuven, VLG, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

An Open-label, Three-center, Randomized, Two-session, Crossover Study, to Assess 4 Days Inpatient, and 6-week Follow-up Home Study Phase Under Remote Monitoring at Only French Centers, the Efficacy and the Safety of the Diabeloop Closed-loop Glucose Control Compared With Sensor-augmented Pump Therapy, in Young Children With Type 1 Diabetes.
An Open-label, Three-center, Randomized, Two-session, Crossover Study, to Assess 4 Days Inpatient, and 6-week Follow-up Home Study Phase Under Remote Monitoring at Only French Centers, the Efficacy and the Safety of the Diabeloop Closed-loop Glucose Control Compared With Sensor-augmented Pump Therapy, in Young Children With Type 1 Diabetes.
Enrollment Status: Completed
Publish Date: March 06, 2020
Intervention Type: Device, Other
Study Phase: Not Applicable

68 Total Publications

Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial.
Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial.
Journal: Lancet (London, England)
Published: July 07, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Casteels's expertise for a condition
ConditionClose
    View All 16 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile